Neves Kattia Cristina, Vieira Sandra Elisabete
. Mestre em Ciências pela Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brasil.
. Médica do Hospital do Servidor Público Estadual de São Paulo (IAMSPE), São Paulo, SP, Brasil.
Rev Assoc Med Bras (1992). 2020 May 15;66(2):187-193. doi: 10.1590/1806-9282.66.2.187.
To analyze clinical and demographic variables possibly associated with the prescriptions of non-recommended but routinely used therapies for infants with acute viral bronchiolitis.
A cross-sectional study included hospitalized infants with bronchiolitis caused by the respiratory syncytial virus. Those with other associated infections and/or morbidities were excluded. The data were collected from medical records.
Among 120 cases, 90% used inhaled beta-agonists, 72.5% corticosteroids, 40% antibiotics, and 66.7% inhaled hypertonic saline solution. The use of bronchodilators did not present an independent association with another variable. More frequent use of corticosteroids was associated with low oximetry, longer hospitalization time, and age>3 months. Antibiotic therapy was associated with the presence of fever, longer hospitalization, and age>3 months. Inhaled hypertonic saline solution was associated with longer hospitalization time.
Non-recommended prescriptions were frequent. Corticosteroid and antibiotic therapy were associated with signs of severity, as expected, but interestingly, they were more frequently used in infants above 3m, which suggested less safety in the diagnosis of viral bronchiolitis in these patients. The use of bronchodilators was even more worrying since they were indiscriminately used, without association with another variable related to the severity or characteristics of the host. The use of the inhaled hypertonic solution, although not associated with severity, seems to have implied a longer hospitalization time. The identification of these conditions of greater vulnerability to the prescription of inappropriate therapies contributes to the implantation of protocols for the bronchiolitis treatment, for continuing education and for analysis of the effectiveness of the strategies employed.
分析可能与急性病毒性细支气管炎婴儿不推荐但常规使用的治疗处方相关的临床和人口统计学变量。
一项横断面研究纳入了因呼吸道合胞病毒引起的细支气管炎住院婴儿。排除有其他相关感染和/或疾病的婴儿。数据从病历中收集。
在120例病例中,90%使用吸入性β-激动剂,72.5%使用皮质类固醇,40%使用抗生素,66.7%使用吸入性高渗盐溶液。支气管扩张剂的使用与其他变量无独立关联。皮质类固醇使用更频繁与低血氧饱和度、住院时间延长和年龄>3个月相关。抗生素治疗与发热、住院时间延长和年龄>3个月相关。吸入性高渗盐溶液与住院时间延长相关。
不推荐的处方很常见。皮质类固醇和抗生素治疗与严重程度迹象相关,正如预期的那样,但有趣的是,它们在3个月以上的婴儿中使用更频繁,这表明这些患者在病毒性细支气管炎诊断中的安全性较低。支气管扩张剂的使用更令人担忧,因为它们被不加区分地使用,与宿主的严重程度或特征的其他变量无关。吸入性高渗溶液的使用虽然与严重程度无关,但似乎意味着住院时间延长。识别这些更容易接受不适当治疗处方的情况有助于实施细支气管炎治疗方案、继续教育以及分析所采用策略的有效性。